- Awaye™ is a unique over-the-counter pain relief cream made
from natural active ingredients
- Awaye™ is clinically tested, non-addictive pain relief
product developed and made in Canada
MONTREAL, Oct. 19, 2021 /CNW/ - Canadians struggling
with chronic pain have a new therapeutic option called Awaye™, a
first of its kind therapy that leverages the body's own
pain-defense mechanism, also known as the endo-cannabinoid system.
Developed by Canadian-based Lumiera Health Innovation, and approved
by Health Canada as a natural health product, Awaye™ is indicated
for those suffering from painful strains and sprains (involving
muscles, tendons and/or ligaments), chronic low back pain, and
arthritis. Awaye™ is a cream applied to the affected areas and is
clinically tested to be safe and effective.
![Awaye™ (CNW Group/Lumiera Health Inc.) Awaye™ (CNW Group/Lumiera Health Inc.)](https://mma.prnewswire.com/media/1663541/Lumiera_Health_Inc__Lumiera_s_new_first_of_its_kind_pain_relief.jpg)
"It is estimated that one in five Canadians live with
chronic pain," said Carlos Ponce,
Chief Executive Officer, Lumiera Health Innovation. "But despite
the number of pain relief products on the market, pain sufferers
are generally dissatisfied with existing options and continue to
search for effective solutions. In some cases, this can lead
to the use of stronger, addictive medications. We know that pain
changes people. Our goal was to develop something that not only
meets a need for a novel pain relief solution, but one backed by
science, that is easily accessible to sufferers and that is safe,
non-addictive and effective. We are proud to say that Awaye™ is the
only topical pain relief product available over-the-counter, that
uses phytocannabinoids, without the use of cannabis, to reduce
pain and inflammation," said Ponce.
Awaye's™ novel formulation combines two agents with
complementary mechanisms of action: capsaicin derived from the
cayenne pepper, and β-caryophyllene. Capsaicin activates the
transient receptor potential vanilloid 1 channel, (TRPV1) a
receptor involved in pain transmission.
β-caryophyllene is a natural terpene found in many essential
oils including clove oil made from the stems and flowers of
Syzygium aromaticum, as well as in rosemary and hops. It activates
the receptors in the body's endo-cannabinoid system (ECS), a
natural pain and anti-inflammation defense system that helps deal
with pain, among other vital functions. β-caryophyllene
specifically activates the cannabinoid type 2 (CB2) receptors to
help decrease pain and inflammation.
"Pain is a common problem, affecting all age groups and
demographics. There are a significant number of Canadians who are
living with moderate to severe pain that interferes with their
daily routine and regular activities. They suffer from a variety of
ailments and conditions including sciatica, low back pain, neck
pain, and sporting injuries. And, in fact, for many pain sufferers,
it can be challenging to find an effective product to control pain
so they can function day-to-day," said Dr. Maher Obeid, a leading Chiropractor and Pain
Management Practitioner.
"Awaye™ is safe, odour-free, non-addictive, and provides huge
relief from acute and chronic pain. Offering my patients a new pain
relief option that complements the existing pain treatments,
therapies and cutting-edge care looks promising. It works well on
pain areas, and the result is the fast and effective relief of
pain," said Dr. Obeid.
"Keeping Canadians healthy, physically active and able to enjoy
sports, exercise and activities of daily living pain free is a tall
order," said Mr. Ponce. "This has been especially difficult over
the past 18 months and exacerbated by a lack of physical activity
and emotional stress that has been experienced. I am confident that
pain sufferers and healthcare professionals will welcome a new
option to manage pain as Canadians get back into their routines or
create new ones."
Awaye™ is available online at awaye.ca and amazon.ca, and soon
over-the-counter in select natural health store channels.
About Lumiera Health Innovation
Lumiera Health
Innovation (a division of Lumiera Health Inc.) is a Canadian-based
natural health product company whose goal is to help improve
people's lives by delivering innovative health products inspired by
nature. As a pioneer in the health and pain management, the Lumiera
brand is rooted in its core values of science, nature, and
compassion.
Passionate about making people feel better,
Lumiera delivers clinically proven solutions that work with
the body's own systems. The name Lumiera signifies progress and
discovery and pays tribute to Professor Lumir Hanus, a recognized pioneer in
understanding the body's own endo-cannabinoid system and how it can
be used to address unmet medical needs. For further information
visit Lumiera at https://www.lumiera.ca
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.